

*Revised as of January, 2014*  
*Revised as of November 2015*  
*Revised as of September 2017*  
*Revised as of July 2018*  
*Revised as of February 2020*

*Revised as of December 2020*  
*Revised as of March 2021*  
*Revised as of September 2021*  
*Revised as of July 2022*  
*Revised as of November 2022*  
*Revised as of March 2023*

The *Korean Circulation Journal (KCJ)* is the official journal of the Korean Society of Cardiology, the Korean Pediatric Heart Society, the Korean Society of Interventional Cardiology, and the Korean Society of Heart Failure. It is an open-access journal publishing monthly in English (<https://www.e-kcj.org>). It is a professional, international, peer-reviewed journal covering all aspects of cardiovascular medicine, including original researches of preclinical and clinical findings, state of the art reviews, perspectives for outbreaking issues, editorials, images in cardiovascular medicine, and letters to the editor. The journal aims to publish highly qualified and novel researches which improve our understanding of cardiovascular disease, educate students and health professionals, give scientific data to researchers and policy makers, and give benefits in clinical practice to general practitioners. KCJ adheres to COPE's Principles of Transparency and Best Practice in Scholarly Publishing and COPE's Core Practices for the overall publication process.

## 1. MANUSCRIPT SUBMISSION

The KCJ has an online submission and peer review system and manuscripts must be submitted electronically at <https://kcj.edmgr.com>. Please first log in as an author and follow the directions. Manuscripts should be submitted by the corresponding author, who must indicate the contact address, phone number, and e-mail for correspondence on the title page of the manuscript. All articles submitted to the Journal must abide by these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. For assistance, please contact us via e-mail, telephone, or fax. Revised manuscripts should be submitted through the same web system under the same manuscript number.

**In-Ho Chae, MD, PhD**

Editor-in-chief, Korean Circulation Journal  
101-1704, Lotte Castle President, 109 Mapo-daero,  
Mapo-gu, Seoul 04146, Korea  
Tel: +82-2-3275-5258, Fax: +82-2-3275-5259  
E-mail: [herz1@circulation.or.kr](mailto:herz1@circulation.or.kr)

## 2. EDITORIAL and PEER REVIEW PROCESS

### 2.1. Peer Review Process

All manuscripts are pre-examined for the format and ethical requirements by managing and ethical consultants, and then decide whether to request external peer review by experts and associate editors in related topics. The authors are blinded when the manuscript is requested for external review. External peer review will be done by at least 2 or more experts in the corresponding field. If needed, editorial staff may request a review from statisticians. The acceptance criteria for all papers are based on the quality and originality of the research and their clinical and scientific contributions in cardiovascular medicine. After request for external review, the initial decision is typically made within 4 weeks with the categories of "accept", "minor revision", "major revision", or "reject". The results of review and the reviewers' comments will be sent to the corresponding author via e-mail. After revision according to the comments and recommendations, the corresponding author must submit the revised manuscript in the same E-submission system.

If manuscripts from Editorial Boards of KCJ are submitted, it is also treated through same process with other manuscripts. However, those authors are not involved in the peer reviewer selection, review process, or final decision.

### 2.2. Revision and Acceptance

When you organize a **revised manuscript**, you should carefully follow the instructions given in the editor's letter. With each revision, KCJ requires two versions of the manuscript to be resubmitted: one with changes tracked or highlighted and one clean version of the revised manuscript. In your response to the reviewers' comments, authors have to address each reviewer comment point-by-point and provide the exact page number(s) and line number(s) where each revision was made in the final clean version of the revised manuscript. Failure to do so will cause a delay in the review of your revision. If references, figures or tables are moved, added, or deleted during the revision process, renumber them to reflect the changes so that all references, figures or tables are cited in numeric order.

Failure to resubmit the revised manuscript within 8 weeks without notification to KCJ is considered to be a withdrawal of the manuscript.

### 2.3. After Decision

#### *Acceptance*

The finally accepted manuscript will be reviewed by a manuscript editor for consistency of format and the completeness of references. The manuscript may be revised according to the style guides of the journal. Before publication, the galley proof will be sent via e-mail to the corresponding author for approval.

#### *Complaints or Appeals*

Authors, reviewers, readers, and submitters may issue complaints or appeals in cases including follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem.

For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.

The Editor, Editorial Board Members including Ethics Consultant, and Editorial Office is responsible for the handling and resolving the submitted complaints and appeals. A Legal Consultant or Ethics Consultant will be involved with the decision making.

The consequence of resolution will depend on the type or degree of the misconduct and will follow the guidelines of the Committee of Publication Ethics (COPE). If not described above, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: <https://publicationethics.org/appeals>.

## 3. ETHICS from RESEARCH to PUBLICATION

All manuscripts should be prepared in strict observation of the research and publication ethics guideline recommended by the International Committee of Medical Journal Editors (ICMJE, available at <http://www.icmje.org>), Council of Science Editors (<https://www.councilscienceeditors.org/>), World Association of Medical Editors (WAME, <http://www.wame.org/>), and the Korean Association of Medical Journal Editors (KAMJE, [https://www.kamje.or.kr/en/main\\_en](https://www.kamje.or.kr/en/main_en)).

All researchers involving animal, cellular, or molecular experiments should record a research note detailing the research process and achievements and follow the research note guidelines of their research institute. If the author's affiliation is different from the institution that conducts the

research, the institution that conducted the research should be marked first, and the original affiliation should be marked separately. KCJ will follow the guideline by the Committee on Publication Ethics (COPE, <http://publicationethics.org/>) for settlement of any misconduct.

### 3.1. Statement of Human and Animal Rights

All clinical research must be performed according to the principles embodied in the Declaration of Helsinki: (<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects>).

Patients have a right to privacy. Therefore, when publishing identifiable images from human research participants, authors must include a statement in the published paper affirming that they have obtained informed consent for publication of the images (unless the consent has waived by an appropriate institutional review board). Images may be cropped to remove nonessential identifying details to protect anonymity but should not be otherwise altered.

Any identifying information, such as patients' names, initials, hospital numbers, or dates of birth should not be included in images, written descriptions, videos, photographs, and pedigrees unless they are essential for scientific purposes. If identifying characteristics are altered to protect anonymity, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Research using animals also should be reviewed by an appropriate committee following the guidelines of the Institutional Animal Care and Use Committee (IACUC). Studies using pathogens requiring a high degree of biosafety should receive permission from a relevant committee such as the Institution Biosafety Committee (IBC).

Authors may be required to provide evidence that they obtained ethical and /or legal approval prior to conducting the research.

### 3.2. Statement of informed Consents and Institutional Review Board Approval

All researches involving human subjects, human material, or human data must be approved by an appropriate institutional review board.

For all research involving human subjects, informed consent to participate in the study should be obtained from the subjects (or their legally authorized representative), if not waived by the institutional review board.

A statement about this, including the name of the ethics committee and the reference number, must be stated in the methods of manuscript. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption).

In the process of submitting the manuscript, authors will be asked if they have obtained the IRB approval and the reference number need to be provided. The editor of the KCJ may request copies of the informed consent and documents of permission from IRB or related committees.

### 3.3. Authorship and Contribution

KCJ follows the recommendations for authorship by the ICMJE, 2019 (<http://icmje.org/icmje-recommendations.pdf>) and Good Publication Practice Guidelines for Medical Journals 3rd Edition (KAMJE, 2019, [https://www.kamje.or.kr/board/view?b\\_name=bo\\_publication&b\\_id=13&per\\_page=](https://www.kamje.or.kr/board/view?b_name=bo_publication&b_id=13&per_page=)).

Authorship credits should be based on 1) substantial contributions to conception or design, acquisition of data, or analysis and interpretation of the data; AND 2) drafting of the manuscript or revising it critically for important intellectual contents; AND 3) final approval of the version to be published; AND 4) agreement to be accountable for all aspects of the work and ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Authors must meet all of these criteria. In addition, an author should be accountable for the parts of the work he or she has done and should be able to identify which co-authors are responsible for specific other parts of the work. Authors should have confidence in the integrity of the contributions of their co-authors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged as contributors not be authors. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion #2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript.

The corresponding author can be only an author(s) who meets all four criteria and cannot be an author who did not meet any one or more of the criteria. The corresponding author should be available throughout the full processes even after publication. When a study is conducted by a large and multicenter group, the group should identify the individual authors who accept responsibility for the manuscript before submission. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as group name. Contributors to the study can be listed in an acknowledgment section. Acquisition of funding, collection of data, or general supervision of the research does not meet

the authorship criteria, and such parties should not be listed as authors. If the corresponding author requests the addition or removal of authors after submission, the editor will assess the reason and a written document regarding agreement from all co-authors. The KCJ has no responsibility for changes in authorship.

### 3.4. Redundant Publication and Plagiarism

Redundant publication is defined as “reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s)”. Characteristics of reports that are substantially similar include the following: (a) “at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant publication),” (b) “the subjects or study populations are the same or overlapped,” (c) “the methodology is typically identical or nearly so,” and (d) “the results and their interpretation generally vary little, if at all.”

When submitting a manuscript, authors should include a letter informing the editor of any potential overlap with other material already published or material being evaluated for publication and should also state how the manuscript submitted to KCJ differs substantially from other materials. If all or part of your patient population was previously reported, this should be mentioned in the Methods, with citation of the appropriate reference(s).

#### 3.4.1 Handling of Misconduct –Corrections & Retractions

KCJ takes all cases of publication misconduct seriously. All reviewers share a responsibility to report any suspected issues with the manuscript to the editor.

If a reviewer or editor raises a concern about suspected cases of research and publication misconduct, such as a redundant publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interests, or an ethical problem, that person should be informed that the Journal editors will perform an investigation. The investigation process will follow the flowchart provided by the Committee on Publication Ethics [COPE] (<https://publicationethics.org/resources/flowcharts>).

If the investigation confirms any scientific misconduct, a retraction of the article will be published. If warranted, the authors will be invited to prepare the retraction, which should be submitted with an assignment of copyright statement that has been signed by all authors. If the paper has not been published, then the editor can always reject the paper.

Instances of misconduct will be shared with the editorial board of the KCJ. The editor may wish to impose sanctions, notify editors of other biomedical journals, and depending on the severity of the allegation, notify the author's institution.

KCJ will not hesitate to publish errata, corrigenda, clarifications,

retractions, and apologies when any misconduct is founded.

### 3.5. Clinical Trials

#### 1) *Obligation to register*

Clinical trial defined as “any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome” should be registered to the primary registry to be prior publication. KCJ accepts the registration in any of the primary registries that participate in the WHO International Clinical Trials Portal (<http://www.who.int/ictrp/en/>), NIH ClinicalTrials.gov (<http://www.clinicaltrials.gov/>), ISRCTN Resister ([www.ISRCTN.org](http://www.ISRCTN.org)), or the Clinical Research Information Service (CRIS), Korea CDC (<https://cris.hih.go.kr/cris/index.jsp>). The clinical trial registration number shall be published at the end of the abstract.

#### 2) *Data sharing statement*

KCJ accepts the ICMJE Recommendations for data sharing statement policy (<http://icmje.org/icmje-recommendations.pdf>). All manuscripts reporting clinical trial results should submit a data sharing statement following the ICMJE guidelines from 1 July 2018.

When the manuscript is submitted, authors should specify the methods of data sharing if it is possible for sharing, otherwise, specify the reason of unable.

Authors may refer to the editorial, “Data Sharing statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors,” in JKMS Vol. 32, No. 7:1051-1053 ([http://crossmark.crossref.org/dialog/?doi=10.3346/jkms.2017.32.7.1051&domain=pdf&date\\_stamp=2017-06-05](http://crossmark.crossref.org/dialog/?doi=10.3346/jkms.2017.32.7.1051&domain=pdf&date_stamp=2017-06-05)).

### 3.6. Conflict of Interest

At manuscript submission, the KCJ requires the corresponding author to summarize all author conflicts of interest disclosures. The conflicts of interest can exist when an author (or author's institution or employer) has financial or personal relationship or affiliations that could have influence on or bias the authors' decisions, works, or the manuscript. Such conflicts can be financial support or private connection to pharmaceutical companies, potential pressure from interest groups, or academic benefits.

The KCJ requires complete disclosure of all relevant financial relationships and potential financial conflicts of interest regardless of amount of value. The corresponding author is asked to inform the Editor of all author conflicts of interest that could influence their interpretation of the data.

At manuscript acceptance, the KCJ can ask the authors to confirm and update their disclosure of conflicts of interest online. At the time of publication, the final status of conflicts of

interest will be disclosed to the readers on <https://www.e-kcj.org>. If any author's disclosure of conflicts of interest is determined to be inaccurate or incomplete after publication, a correction will be published to rectify the original published disclosure statement, and additional action can be taken as necessary.

### 3.7. Funding

All sources of funding for the study should be listed explicitly and declared under the title of ‘Funding’. The roles of funders were stated in the manuscript including study design, data collection, analysis, any decisions in publication, or preparation of manuscript.

All forms are now signed and submitted electronically. Once the revision manuscript is submitted, the authors will be sent links to complete the electronic Relationship with Industry form and all authors are required to electronically sign a relationship with industry form. Once completed, the further process will be started. Only authors appearing on the final title page will be sent a form.

## 4. EDITORIAL POLICY

The editorial staffs assume that all authors agreed with the KCJ policies of manuscript submission. Except for the preapproved secondary publication by editor-in-chief, all manuscripts submitted to KCJ must not be previously published in all languages and not be under consideration for submission or publication in other journals. The identities of decision makers will not be disclosed in any circumstances.

## 5. MANUSCRIPT PREPARATION AND FORMAT

The manuscript should be prepared according to “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations, formerly the Uniform Requirements for Manuscripts)” (<http://www.icmje.org>).

All materials must be written in clear, appropriate English using Microsoft Word (doc) or other major word-processing programs. The manuscript must be double-spaced in 12-point font with 1-inch margin on both sides, top, and bottom on A4 sized paper or North American letter-sized paper.

#### *Author's summary*

The authors of original researches, state of the art reviews, perspectives of the outbreaking issues have to summarize the articles consisting of; what are the unmet needs, important findings for the unmet needs and scientific and clinical meanings of the article. Avoid copying the part of abstract and exceeding 100 words.

## INSTRUCTIONS FOR AUTHORS

### Representative image

Select one figure which is representing the finding of the articles of original researches, state of the art reviews, perspectives of the outbreking issues, images of cardiovascular medicine.

### 5.1. Original Researches

- Clinical Investigation and Reports: Studies conducted in humans or analysis of human data
- Basic Science Reports: Studies conducted in animals and in vitro experiments
- Word count:  $\leq 5000$  words excluding the title page, abstract, and tables
- Structured abstract:  $\leq 250$  words with the following sections: Background and Objectives, Methods, Results, Conclusions. Use complete sentences. All data in the abstract also must appear in the manuscript text or tables
- Keywords: Three to five keywords from the Medical Subject Headings (MeSH) list of Index Medicus
- Number of references:  $\leq 30$
- Number of figures and tables:  $\leq 8$
- Graphic abstract: Pictorial form designed image representing the finding of the articles of the research should be included.

The manuscript should be arranged in the following sequence: 1) Title Page, 2) Abstract, 3) Keywords, 4) Text, 5) Acknowledgements (if applicable), 6) Funding, 7) Disclosures 8) References, 9) Figure Legends, 10) Figures, 11) Tables, and 12) Supplemental Materials. Page numbering should begin with the Title Page.

### Title Page

The title page should appear as follows; the title of the manuscript, a short title, names of all authors with their academic degrees and ORCID IDs, total word count of the manuscript, conflict of interests, and funding statement.

- Full title
- Short title (not to exceed 45 characters including spaces)
- Authors' names including academic degrees and ORCID IDs.
- The contact information for correspondence and reprints, including name, academic degree(s), address (institutional affiliation, city, zip code, and country), telephone and fax numbers, and e-mail address. The corresponding author will be the sole contact for all submission queries.
- Total word count: Include main text, acknowledgement, references, and figure legends. Exclude the title page, abstract, and tables.
- Funding statements: Describe the sources of funding that have supported the work with relevant grant numbers. Please also describe the role of any sponsors or funders and if they had no role, include the following statement at the

end of your statement: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

- Conflict of Interest: Any potential conflicts of interest relevant to the manuscript should be described. If there are no conflicts of interest, authors should state that none exists.

### Abstract

- Do not cite references in the abstract.
- Limit use of acronyms and abbreviations. Define acronym or abbreviation at its first use in parentheses.
- A structured abstract of no more than 250 words for Original Researches
- Use the following four headings in Original Researches
  - Background and Objectives: Rationale for study
  - Methods: Brief presentation of study design and key methods
  - Results: Succinct presentation of key results; please include sample sizes
  - Conclusions: Succinct statement of data interpretation
- All data in the abstract also must appear in the manuscript text or tables.
- The clinical trial registration number shall be published at the end of the abstract.

### Keywords

Provide three to five keywords from the Medical Subject Headings (MeSH) list of Index Medicus: <http://www.nlm.nih.gov/mesh>

### Text

- The text of Original Researches should be structured using the main headings of Introduction, Methods, Results, and Discussion.
- Abbreviations must be defined at first mention in the text and each table and figure.
- Every reference, figure, and table should be cited in the text in numerical order according to order of mention.
- Ethical Approval (required): Please denote that your study received the proper ethical oversight **in both your cover letter and your Methods section**. For manuscripts reporting data on human subjects, note institutional review board/ethics committee approval (or formal review and exemption), including **the specific name of the board or committee and the reference number**. For studies involving animal experiments, note that the study complied with all institutional and national requirements for the care and use of laboratory animals and, if applicable, received animal care and use committee approval.
  - Experimental animals: State the species, strain, number used, and pertinent descriptive characteristics.

## INSTRUCTIONS FOR AUTHORS

When describing surgical procedures, identify the preanesthetic and anesthetic agents used and the amounts, concentrations, routes, and frequency of administration of each. Paralytic agents are not considered acceptable substitutes for anesthetics. For other invasive procedures on animals, report the analgesic or tranquilizing drug used. If none were used, provide justification for exclusion.

- Human studies: Indicate that the study was approved by an institutional review board along with the name of the IRB, and that the participants gave written informed consent (or that no informed consent was required).
- Studies of medications, biologics, and devices: Generic rather than trademark names of all therapeutics should be used.

### Acknowledgments

All non-author contributors who did not meet the criteria of author by ICMJE can be listed in the acknowledgments section.

### Funding

Describe the sources of funding that have supported the work with relevant grant numbers. Please also describe the role of any sponsors or funders and if they had no role, include the following statement at the end of your statement: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

### Disclosure of conflicts of interest

Any potential conflicts of interest relevant to the manuscript should be described. If there are no conflicts of interest, authors should state that none exists.

### References

- The description of a journal reference follows the below description. Otherwise, it follows the NLM Style Guide for Authors, Editors, and Publishers: Patrias, K. Citing medicine: the NLM style guide for authors, editors, and publishers [Internet]. 2nd ed. Wendling, DL, technical editor. Bethesda (MD): National Library of Medicine (US); 2007 [updated 2009 Jan 14; cited 2009 June 25]. Available from: <http://www.nlm.nih.gov/citingmedicine>
- Accuracy of reference data is the responsibility of the author.
- Verify all references against original sources.
- The reference list should be typed double-spaced on pages separate from the text; references must be numbered consecutively in the order in which they are mentioned in the text. List all authors if 6 or fewer; otherwise, list the first 3 and add "et al."
- Names of journals should be abbreviated in the style used in Index Medicus.
- Overall format of references is as follows:

Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1995;20:1301-7.

- Books can be cited as follows:  
Hinohara T, Robertson CG, Simpson JB. Directional coronary atherectomy. In: Topol EJ, editor. *Textbook of Interventional Cardiology*. 2nd ed. Philadelphia: W.B. Saunders Company; 1994. p.645-57.
- Do not cite abstracts older than 2 years. Abstracts can be cited as follows:  
Sweeney RJ, Gill RM, Reid PR. Increased action potential prolongation by low voltage biphasic versus monophasic field stimulation. *J Am Coll Cardiol* 1995;86A. Abstract
- Personal communications, unpublished observations, and submitted manuscripts are not legitimate references. They must be cited in the text only (not the reference list).
- If an article has been published online but has not yet been given an issue or pages, the digital object identifier (DOI) should be supplied.

### Figure Legends

- All figures must have a number, title, and caption.
- Figures should be cited in numerical order in the text.
- Figure titles should be short and followed by a 2 to 3 sentence caption.
- Figure Legends should be typed double-spaced on pages separate from the text.
- All abbreviations should be identified in alphabetical order at the end of each legend.

### Figures

- Figures and graphs should be provided in GIF, TIFF, EPS, or JPG format.
- Color and Gray scale images must be at least 300 DPI. The smallest parts of a figure should be legible when they are reduced to the final print size.
- If the number of files is more than five, one PowerPoint file is acceptable.
- Figure numbers must correspond with the order in which they are mentioned in the text.
- All abbreviations used in the figure should be identified in alphabetical order at the end of each legend.
- All symbols used (arrows, circles, etc.) must be explained.
- If previously published figures are used, written permission from the original publisher is required. See STM Guidelines for details: <http://www.stm-assoc.org/copyright-legal-affairs/permissions/permissions-guidelines>.
- Symbols, arrows, or letters used in photographs should contrast the background visually. The legend for each light microscopic image should indicate the stain used and the

## INSTRUCTIONS FOR AUTHORS

level of magnification. Electron micrographs should have an internal magnification scale marker. All types of figure can be reduced, enlarged, or trimmed for publication by the editor.

- Supply a scale bar with photomicrographs.

### Tables

- Begin each table on a separate page, double-spaced.
- The table number should be Arabic, followed by a period and brief title.
- Table numbers must correspond with the order cited in the text.
- Tables should be self-explanatory, and the data presented in them should not be duplicated in the text or figures.
- Do not use vertical lines between columns. Use horizontal lines above and below the column headings and at the bottom of the table only. Use extra spaces to delineate sections within the table.
- Abbreviations used in the table must be defined in a footnote to the table.
- Indicate footnotes in this order: \*, †, ‡, §, ||, ¶, #, \*\*.

### Supplemental Materials

Supplemental materials will be provided in the online version only. Such materials can consist of 1) Information that cannot be printed, such as animations, video clips, and sound recordings, 2) Information that can be presented more conveniently in electronic form, AND 3) Large original data, e.g., additional tables or illustrations.

- Submission
  - Submit all supplemental materials in standard file formats.
  - All submitted supplemental materials must be mentioned in the manuscript.
  - All supplemental materials can be submitted with your article in the E-Submission System.
- Multimedia files
  - Multimedia files should be accompanied by brief relevant information explaining the content of the audio, video, or animation files.
  - Please ensure that all researchers featured in the multimedia files have given permission for publication. Written consent must be submitted.
  - Audio material should preferably be submitted as an MP3 file, no larger than 10 MB.
  - Video material should be submitted in a standard format such as MPEG-2, MPEG-4, H.264, WMV, QuickTime codec with QuickTime (MOV), AVI, or MP4 and be no larger than 10 MB.
  - The URL address will be provided in the offline journal and will link to the video in the online journal. Videos

should be numbered in the order they appear in the text.

- If your files are larger than 10 MB, please contact the Korean Circulation Journal's editorial office.
- Text and Presentations
  - Submit your material as a PDF, DOC, or PPT file.
  - A collection of figures can also be combined in a single file.

### 5.2. State of the Art Reviews

Concise and comprehensive articles devoted to review a topic from basic mechanisms to clinical manifestations and interventional approaches to global health implications comprise this category. Most review articles are invited by the Editors; however, unsolicited material might also be considered for publication. If you wish to submit a review article to the journal, please do so via <https://e-kcj.org> our submission site.

- Word count: ≤ 10,000 words excluding tables
- Unstructured abstract: ≤ 250 words
- Keywords: Three to five keywords from the Medical Subject Headings (MeSH) list of Index Medicus
- Reference limit: None

Clinical Practice Guideline submissions must be proposed to and approved by the Editor-in-Chief prior to submission. Please submit proposals to [herz1@circulation.or.kr](mailto:herz1@circulation.or.kr). After the approval, the editorial office will contact the corresponding author(s) to proceed further steps.

### 5.3. Perspectives for Outbreaking Issues

Perspectives for outbreaking issues are brief and timely articles for the newly emerging or debating issues in cardiovascular medicine. Both invited and unsolicited articles can be published after peer-review by experts and editor on related fields.

- Word count: ≤ 2,000 words excluding tables and figures
- Unstructured abstract: ≤ 250 words
- Keywords: three to five words from the Medical Subject Headings (MeSH) list of Index Medicus
- Reference limit: ≤ 25
- Number of figures and tables: ≤ 4

### 5.4. Editorials

Editorials are commentaries on articles that appear in the journal and are invited by the editors. Editorial topics could include active areas of research, fresh insights, and debates in all fields of cardiovascular medicine. If you are invited to write an editorial, specific requirements will be sent to you. Please do not submit unsolicited editorials.

- Number of references: ≤ 10

### 5.5. Images in Cardiovascular Medicine

Clinical images illustrate either important or novel findings and provide insight into diagnosis and mechanisms responsible for

## INSTRUCTIONS FOR AUTHORS

cardiovascular medicine. The maximum number of authors for images in cardiovascular medicine is 8.

- Word count:  $\leq 250$  words
- Number of references:  $\leq 5$

### 5.6. Letters to the Editor

Letters to the Editor focus on a specific article published in KCJ within 6 months of the issue date. We will seek a reply to your letter from the authors of the original paper and publish both together.

- Word count:  $\leq 500$  words including references
- Number of references:  $\leq 5$
- Number of Authors:  $\leq 3$
- Number of figures and tables:  $\leq 1$

The decision will be made by the reviewers who reviewed the original articles.

### 5.7. Research Letter

Research Letter is the original investigations of a focused nature.

- Word count:  $\leq 800$
- Number of references:  $\leq 5$
- Number of Authors:  $\leq 10$  (Co-first author, Co-corresponding authors are not allowed)
- Number of figures and tables:  $\leq 1$
- Supplementary Materials are not allowed

## 6. REVISED MANUSCRIPTS

When you organize a revised version of your manuscript, you should carefully follow the instructions given in the editor's letter. Please submit both a clean copy of your manuscript and an annotated copy describing the changes you have made. Failure to do so will cause a delay in the review of your revision. If references, figures or tables are moved, added, or deleted during the revision process, renumber them to reflect the changes so that all references, figures or tables are cited in numeric order.

The annotated copy should have changes by red or highlighted (either using the Track Changes function in MS Word), with notes in the text referring to the editor or reviewer queries.

## 7. COPYRIGHT

All published papers will become the permanent property of the Korean Society of Cardiology and must not be published elsewhere without written permission from the Society. A copyright transfer agreement form should be submitted electronically on the submission website. This form is identical to the Creative Commons (Attribution-Noncommercial) at: <https://creativecommons.org/licenses/by-nc/4.0/legalcode>.

## 8. AUTHOR REPRINTS

Inquiries for reprints for educational, commercial, or promotional use can be directed to:

### Korean Circulation Journal Editorial office

101-1704, Lotte Castle President, 109 Mapo-daero,

Mapo-gu, Seoul 04146, Korea

Tel: 82-2-3275-5258, Fax: 82-2-3275-5259

E-mail: [herz1@circulation.or.kr](mailto:herz1@circulation.or.kr)

- ☐ Double-spaced type on A4 size (white) paper with Times New Roman 12-point font.
- ☐ All pages should be numbered consecutively starting from the title page.
- ☐ Sequence in the case of an Original Research is title page, abstract and keywords, introduction, methods, results, discussion, acknowledgments, references, figure legends, figures, tables, and supplemental Materials.
- ☐ Title page with article title, authors' full name(s) and affiliation(s), information of correspondence (including address, telephone and fax numbers, and e-mail), short title (less than 45 characters including spaces), and footnotes if any.
- ☐ Abstract in structured format within 250 words and a maximum of 5 keywords as in MeSH in Original Researches.
- ☐ All table and figure numbers are presented in the text.
- ☐ References are assessed for accuracy and listed in proper format. Check that all references listed in the references section are cited in the text.
- ☐ Figures are professional and in an acceptable format.

The Korean Circulation Journal has an online submission and peer review system. Manuscripts should be submitted online at <http://kcj.edmgr.com>.

## Online Submission of Original Manuscripts

Log on to <http://kcj.edmgr.com>. If you do not have an account, click on the “Register Now” link. If you have an account, but do not know your password, click on the “Send Login Details” link. Otherwise, enter your Username and Password into the boxes provided, and click “Login” that you belong to. On the welcome page, click on “Submit New Manuscript” and select the appropriate article type. Click on “Link to ORCID Record” to authenticate your ORCID. After that, follow the steps to submit a new manuscript.

For further information on how to use the online submission system, please feel free to contact us:

**In-Ho Chae, MD**

Editor-in-chief

Korean Circulation Journal

101-1704, Lotte Castle President, 109 Mapo-daero,

Mapo-gu, Seoul 04146, Korea

Tel: +82-2-3275-5258, Fax: +82-2-3275-5259

E-mail: [herz1@circulation.or.kr](mailto:herz1@circulation.or.kr)

---

## Revision after Review and Uploading the Final Manuscript

After review, we inform the corresponding author by e-mail of the decision to publish the manuscript. After being informed, the author should log in to our website and check the category “Revisions” to upload the final manuscript. Images can be uploaded in GIF, TIFF, EPS, and JPG form or be included as a PPT. Each image should have the same name as described in the manuscript (ex. Figure 1A).